Minerva Neurosciences (NASDAQ:NERV) Price Target Lowered to $4.00 at HC Wainwright

Minerva Neurosciences (NASDAQ:NERV) had its price target lowered by HC Wainwright from $5.00 to $4.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Minerva Neurosciences’ Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.09) EPS and FY2029 earnings at $0.61 EPS.

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Minerva Neurosciences in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $4.00.

Minerva Neurosciences Stock Up 1.9%

NERV traded up $0.07 during trading hours on Thursday, reaching $3.71. The company’s stock had a trading volume of 123,082 shares, compared to its average volume of 904,357. Minerva Neurosciences has a 52 week low of $1.15 and a 52 week high of $12.46. The company’s 50-day moving average is $2.87 and its 200-day moving average is $2.18.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). As a group, research analysts expect that Minerva Neurosciences will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Apella Capital LLC grew its position in shares of Minerva Neurosciences, Inc (NASDAQ:NERV) by 87.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 39,314 shares of the biopharmaceutical company’s stock after purchasing an additional 18,375 shares during the quarter. Apella Capital LLC’s holdings in Minerva Neurosciences were worth $83,000 as of its most recent SEC filing. 34.56% of the stock is currently owned by institutional investors and hedge funds.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.